Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;92(5):494-501.
doi: 10.1136/jnnp-2020-323541. Epub 2021 Jan 15.

Modelling the cascade of biomarker changes in GRN-related frontotemporal dementia

Collaborators, Affiliations

Modelling the cascade of biomarker changes in GRN-related frontotemporal dementia

Jessica L Panman et al. J Neurol Neurosurg Psychiatry. 2021 May.

Abstract

Objective: Progranulin-related frontotemporal dementia (FTD-GRN) is a fast progressive disease. Modelling the cascade of multimodal biomarker changes aids in understanding the aetiology of this disease and enables monitoring of individual mutation carriers. In this cross-sectional study, we estimated the temporal cascade of biomarker changes for FTD-GRN, in a data-driven way.

Methods: We included 56 presymptomatic and 35 symptomatic GRN mutation carriers, and 35 healthy non-carriers. Selected biomarkers were neurofilament light chain (NfL), grey matter volume, white matter microstructure and cognitive domains. We used discriminative event-based modelling to infer the cascade of biomarker changes in FTD-GRN and estimated individual disease severity through cross-validation. We derived the biomarker cascades in non-fluent variant primary progressive aphasia (nfvPPA) and behavioural variant FTD (bvFTD) to understand the differences between these phenotypes.

Results: Language functioning and NfL were the earliest abnormal biomarkers in FTD-GRN. White matter tracts were affected before grey matter volume, and the left hemisphere degenerated before the right. Based on individual disease severities, presymptomatic carriers could be delineated from symptomatic carriers with a sensitivity of 100% and specificity of 96.1%. The estimated disease severity strongly correlated with functional severity in nfvPPA, but not in bvFTD. In addition, the biomarker cascade in bvFTD showed more uncertainty than nfvPPA.

Conclusion: Degeneration of axons and language deficits are indicated to be the earliest biomarkers in FTD-GRN, with bvFTD being more heterogeneous in disease progression than nfvPPA. Our data-driven model could help identify presymptomatic GRN mutation carriers at risk of conversion to the clinical stage.

PubMed Disclaimer

Conflict of interest statement

Competing interests: RS-V received personal fees for participating in advisory meetings from Wave pharmaceuticals and Ionis.

Figures

Figure 1
Figure 1
Cascade of biomarker changes in FTD-GRN along with the uncertainty associated with it. (A) Non-imaging biomarkers. (B) Multimodal biomarkers with Siamese GMM. (C) Multimodal biomarkers without Siamese GMM. The biomarkers are ordered based on the position in the estimated cascade. The colour map is based on the number of times a biomarker is at a position in 100 repetitions of bootstrapping. FTD-GRN, progranulin-related frontotemporal dementia; GMM, Gaussian mixture modelling.
Figure 2
Figure 2
Gaussian mixture modelling (GMM) distributions. The histogram bins are divided in three colours, where the green part shows the proportion of non-carriers, the yellow part shows the proportion of presymptomatic carriers and the red part shows the proportion of symptomatic carriers. The Gaussians shown here are the ones that were estimated using GMM, where the green Gaussian is the normal one estimated using non-carriers and the red Gaussian is the abnormal one estimated using the carriers. The amplitudes of these Gaussians are based on the estimated mixing parameter. The grey curve shows the total estimated distribution, which is the summation of green and red Gaussians.
Figure 3
Figure 3
Frequency of occurrence of subjects with different disease severities, estimated using cross-validation. (A) Results using non-imaging biomarkers in discriminative event-based modelling (DEBM). (B) Results using multimodal biomarkers in DEBM.
Figure 4
Figure 4
Correlation of disease severity (as estimated by multimodal DEBM using cross-validation) with years since onset and FTD-CDR-SOB. The 2D scatter plots in subfigures A and C show the correlations of disease severity with years since onset, for symptomatic nfvPPA and bvFTD subjects, respectively. The 2D scatter plot in subfigures B and D show the correlations of disease severity with FTD-CDR-SOB. The plot on top of each subfigure shows the probability density function of the disease stages. The plots on the right of subfigures A and C show the probability density functions of years since symptom onset. The plots on the right of subfigures B and D show the probability density function of FTD-CDR-SOB. 2D, two-dimensional; bvFTD, behavioural variant frontotemporal dementia; DEBM, discriminative event-based modelling; FTD-CDR-SOB, Frontotemporal Lobar Degeneration Clinical Dementia Rating Scale Sum of Boxes; nfvPPA, non-fluent variant primary progressive aphasia.
Figure 5
Figure 5
Cascade of multimodal biomarker changes in nfvPPA (A) and bvFTD (B) subjects along with the uncertainty associated with it. The biomarkers are ordered based on the position in the estimated cascade. The colour map is based on the number of times a biomarker is at a position in 100 repetitions of bootstrapping. bvFTD, behavioural variant frontotemporal dementia; nfvPPA, non-fluent variant primary progressive aphasia.

Similar articles

  • White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study.
    Sudre CH, Bocchetta M, Heller C, Convery R, Neason M, Moore KM, Cash DM, Thomas DL, Woollacott IOC, Foiani M, Heslegrave A, Shafei R, Greaves C, van Swieten J, Moreno F, Sanchez-Valle R, Borroni B, Laforce R Jr, Masellis M, Tartaglia MC, Graff C, Galimberti D, Rowe JB, Finger E, Synofzik M, Vandenberghe R, de Mendonça A, Tagliavini F, Santana I, Ducharme S, Butler C, Gerhard A, Levin J, Danek A, Frisoni GB, Sorbi S, Otto M, Zetterberg H, Ourselin S, Cardoso MJ, Rohrer JD; On behalf of, GENFI. Sudre CH, et al. Neuroimage Clin. 2019;24:102077. doi: 10.1016/j.nicl.2019.102077. Epub 2019 Nov 6. Neuroimage Clin. 2019. PMID: 31835286 Free PMC article.
  • Disease-modifying effects of TMEM106B in genetic frontotemporal dementia: a longitudinal GENFI study.
    Mirza SS, Pasternak M, Paterson AD, Rogaeva E, Tartaglia MC, Mitchell SB, Black SE, Freedman M, Tang-Wai D, Bouzigues A, Russell LL, Foster PH, Ferry-Bolder E, Bocchetta M, Cash DM, Zetterberg H, Sogorb-Esteve A, van Swieten J, Jiskoot LC, Seelaar H, Sanchez-Valle R, Laforce R Jr, Graff C, Galimberti D, Vandenberghe R, de Mendonça A, Tiraboschi P, Santana I, Gerhard A, Levin J, Sorbi S, Otto M, Pasquier F, Ducharme S, Butler C, Le Ber I, Finger E, Rowe JB, Synofzik M, Moreno F, Borroni B, Rohrer JD, Masellis M; GENetic Frontotemporal dementia Initiative (GENFI). Mirza SS, et al. Brain. 2025 Aug 1;148(8):2746-2762. doi: 10.1093/brain/awaf019. Brain. 2025. PMID: 40260680 Free PMC article.
  • Longitudinal multimodal MRI as prognostic and diagnostic biomarker in presymptomatic familial frontotemporal dementia.
    Jiskoot LC, Panman JL, Meeter LH, Dopper EGP, Donker Kaat L, Franzen S, van der Ende EL, van Minkelen R, Rombouts SARB, Papma JM, van Swieten JC. Jiskoot LC, et al. Brain. 2019 Jan 1;142(1):193-208. doi: 10.1093/brain/awy288. Brain. 2019. PMID: 30508042 Free PMC article.
  • Blood-Based Biomarkers in Frontotemporal Dementia: A Narrative Review.
    Liampas I, Kyriakoulopoulou P, Karakoida V, Kavvoura PA, Sgantzos M, Bogdanos DP, Stamati P, Dardiotis E, Siokas V. Liampas I, et al. Int J Mol Sci. 2024 Nov 4;25(21):11838. doi: 10.3390/ijms252111838. Int J Mol Sci. 2024. PMID: 39519389 Free PMC article. Review.
  • An update on genetic frontotemporal dementia.
    Greaves CV, Rohrer JD. Greaves CV, et al. J Neurol. 2019 Aug;266(8):2075-2086. doi: 10.1007/s00415-019-09363-4. Epub 2019 May 22. J Neurol. 2019. PMID: 31119452 Free PMC article. Review.

Cited by

References

    1. Seelaar H, Rohrer JD, Pijnenburg YAL, et al. . Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry 2011;82:476–86. 10.1136/jnnp.2010.212225 - DOI - PubMed
    1. van Swieten JC, Heutink P. Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurol 2008;7:965–74. 10.1016/S1474-4422(08)70194-7 - DOI - PubMed
    1. Mann DMA, Snowden JS. Frontotemporal lobar degeneration: pathogenesis, pathology and pathways to phenotype. Brain Pathol 2017;27:723–36. 10.1111/bpa.12486 - DOI - PMC - PubMed
    1. Woollacott IOC, Rohrer JD. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. J Neurochem 2016;138 Suppl 1: :6–31. 10.1111/jnc.13654 - DOI - PubMed
    1. Chitramuthu BP, Bennett HPJ, Bateman A. Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease. Brain 2017;140:3081–104. 10.1093/brain/awx198 - DOI - PubMed

Publication types

MeSH terms